Eli Lilly and Company successfully challenged the domain ‘mounjaro-ozempic.online’, which was used to redirect traffic to competitor GLP-1 pharmaceutical products. The WIPO panel ordered the transfer of the domain to the complainant due to trademark infringement and bad faith registration by the respondent.
Case Snapshot
| Case Number | D2026-4028 |
|---|---|
| Complainant | Eli Lilly and Company |
| Respondent | Yuuichi Yoshida, Yoshida Yuuichi |
| Disputed Domain | mounjaro-ozempic.online |
| Threat Tactic | Traffic Diversion |
| Decision Date | 2026-11-03 |
| Panelist | Douglas Clark |
| Outcome | Transfer |
| Official Source | https://www.wipo.int/amc/en/domains/search/text.jsp?case=D2026-4028 |
Facing Unauthorized Domain Registrations or Brand Abuse?
Our domain dispute attorneys represent trademark owners and businesses worldwide before WIPO, Forum (NAF), and CAC. Explore our Domain Name Disputes and Enforcement & Takedowns services, or request a free case evaluation.
Request Case EvaluationStrategic Risk of Brand-Plus-Keyword Traffic Diversion in Pharmaceutical Markets
The use of ‘mounjaro-ozempic.online’ highlights a critical business risk where trademark-heavy domain strings are weaponized to facilitate commercial traffic diversion. By pairing the MOUNJARO trademark with competing GLP-1 medication names like Ozempic, Wegovy, and Saxenda, the respondent created a digital gateway designed to intercept high-intent traffic. This tactic not only erodes the exclusivity of the brand’s digital presence but also presents a significant risk to customer trust by funneling patients toward third-party sites that may offer unregulated or compounded pharmaceutical alternatives, effectively compromising the brand’s control over the user experience and safety narrative.
The respondent’s established pattern of bad faith, previously identified in WIPO Case No. D2026-2671, signals a targeted methodology rather than an isolated incident. For pharmaceutical brand owners, this behavior poses an ongoing threat to market integrity, as repeat actors utilize domain registration to exploit brand equity for the benefit of competitors. The diversion of consumers to sites promoting both the complainant’s product and various competitor treatments complicates market positioning and creates unnecessary confusion. Addressing these threats requires proactive vigilance and a robust UDRP strategy, particularly against entities that leverage multi-brand domain aggregation to artificially elevate traffic to competing pharmaceutical platforms.
Panel Analysis of Confusing Similarity, Legitimate Interests, and Bad Faith
In evaluating the first element of the UDRP, the Panel determined that the disputed domain name, ‘mounjaro-ozempic.online’, is confusingly similar to Eli Lilly’s well-known MOUNJARO trademark. The Panel affirmed that the first element functions as a standing requirement, finding that the domain incorporates the complainant’s mark in its entirety. This assessment confirms that the inclusion of third-party pharmaceutical trademarks, such as ‘ozempic’, does not mitigate the confusion arising from the unauthorized use of the complainant’s primary mark within the domain string.
Regarding the second element, the Panel held that the respondent, Yuuichi Yoshida, possesses no rights or legitimate interests in the disputed domain. The evidence showed no connection between the respondent and the domain, nor any indication of a bona fide offering of goods or services or legitimate noncommercial use. The respondent failed to provide a formal response or rebut the complainant’s evidence, leading the Panel to conclude that the registration was devoid of any permissible justification or fair-use defense.
The finding of bad faith was heavily supported by the respondent’s clear intent to capitalize on the complainant’s brand for commercial gain. By redirecting users to sites promoting competing GLP-1 medications—including Wegovy and Saxenda—the respondent demonstrated a pattern of diverting traffic for competitive advantage. Furthermore, the Panel noted that the respondent was previously identified as acting in bad faith in WIPO Case No. D2026-2671. This recurring behavior confirms that the respondent actively uses trademark-encumbered domains to facilitate unauthorized commercial redirection, reinforcing the necessity for the transfer of the domain.
Strategic Enforcement Against Multi-Brand Domain Diversion
The success of Eli Lilly’s complaint in case D2026-4028 relied on clearly demonstrating that the domain ‘mounjaro-ozempic.online’ was systematically designed to intercept consumer traffic by pairing the complainant’s well-known MOUNJARO trademark with direct competitor brands. By documenting that the domain redirected users to sites promoting competing GLP-1 medications like Ozempic, Wegovy, and Saxenda, the complainant effectively established a clear pattern of commercial exploitation. This strategy successfully framed the domain registration not merely as cybersquatting, but as an aggressive traffic diversion tactic intended to leverage the brand’s equity for the benefit of competing pharmaceutical products, which was pivotal in satisfying the bad faith element of the UDRP.
Furthermore, the complainant’s procedural strategy was essential in navigating the jurisdictional challenges posed by the Japanese-language registration agreement. By promptly requesting that English be designated as the language of the proceeding and providing evidence of the respondent’s history of bad faith—specifically referencing WIPO Case No. D2026-2671—Eli Lilly strengthened its position despite the respondent’s failure to participate. The evidence of a repeat offender combined with the aggressive inclusion of third-party trademarks within the domain string provided the panel with sufficient justification to order a transfer. This approach serves as a robust model for brand owners dealing with entities that use multi-brand aggregation to dilute trademark strength and deceive potential patients searching for authorized medication sources.
Practical Recommendations
- Prioritize proactive monitoring of domain registrations that combine your core brand with direct competitor product names, as these are high-risk indicators of commercial traffic diversion.
- When filing UDRP complaints against repeat offenders, proactively cite their history in other WIPO proceedings (e.g., Case No. D2026-2671) to establish a clear pattern of bad faith.
- Implement language-neutral procedural strategies in your UDRP complaints from the outset to avoid delays caused by registration agreements in foreign languages; include a request for English as the language of the proceeding in the initial filing.
- Flag traffic-diversion sites to your digital brand protection team specifically for regulatory and safety reviews, as unauthorized aggregation sites often obscure compounding risks that can impact your brand’s reputation and patient safety.
Frequently Asked Questions (FAQ)
How did the disputed domain ‘mounjaro-ozempic.online’ create consumer confusion?
The domain name incorporated Eli Lilly’s well-known ‘MOUNJARO’ trademark in its entirety alongside the competitor brand ‘ozempic’. This structure misled users by implying an official affiliation with or authorized comparison of these pharmaceutical products, creating a high risk of consumer confusion regarding the source of the website.
What evidence established the respondent’s bad faith in this case?
The panel found bad faith because the respondent used the domain to intentionally divert traffic to third-party sites promoting both Eli Lilly’s Mounjaro and competing GLP-1 medications, such as Wegovy and Saxenda, for commercial gain. Additionally, the respondent was previously found to have engaged in bad faith in WIPO Case No. D2026-2671, demonstrating a pattern of targeting trademarks.
Did the respondent provide any legitimate justification for using the domain?
No. The respondent failed to provide a formal response to the complaint. The panel found no evidence that the respondent was commonly known by the domain name or was engaged in a bona fide offering of goods or services, concluding that the respondent lacked any rights or legitimate interests in the disputed domain.
How was the language of the proceeding resolved given the Japanese registration agreement?
Although the registration agreement for the domain was in Japanese, the complainant requested that English be the language of the proceeding. Since the respondent did not submit any comments or objections to this request, and considering the circumstances, the panel designated English as the language of the proceeding under paragraph 11(a) of the Rules.
Is your brand traffic being hijacked to competitor sites?
Don’t let third-party domains siphon your hard-earned traffic to competitor products. We help brand teams assess UDRP eligibility to shut down deceptive redirects and recover hijacked domains.
This case note is for informational purposes only and is not legal advice.